[go: up one dir, main page]

ATE516367T1 - USE OF A GENETIC MODIFICATION IN THE HUMAN GNAS GENE TO PREDICT RISK OF DISEASE, DISEASE PROCESSES AND TO PREDICT RESPONSE TO DISEASE THERAPIES - Google Patents

USE OF A GENETIC MODIFICATION IN THE HUMAN GNAS GENE TO PREDICT RISK OF DISEASE, DISEASE PROCESSES AND TO PREDICT RESPONSE TO DISEASE THERAPIES

Info

Publication number
ATE516367T1
ATE516367T1 AT04712508T AT04712508T ATE516367T1 AT E516367 T1 ATE516367 T1 AT E516367T1 AT 04712508 T AT04712508 T AT 04712508T AT 04712508 T AT04712508 T AT 04712508T AT E516367 T1 ATE516367 T1 AT E516367T1
Authority
AT
Austria
Prior art keywords
disease
predict
genetic modification
therapies
processes
Prior art date
Application number
AT04712508T
Other languages
German (de)
Inventor
Ulrich Frey
Winfried Siffert
Original Assignee
Univ Duisburg Essen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32797558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE516367(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duisburg Essen filed Critical Univ Duisburg Essen
Priority claimed from PCT/EP2004/001563 external-priority patent/WO2004076690A2/en
Application granted granted Critical
Publication of ATE516367T1 publication Critical patent/ATE516367T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04712508T 2003-02-19 2004-02-19 USE OF A GENETIC MODIFICATION IN THE HUMAN GNAS GENE TO PREDICT RISK OF DISEASE, DISEASE PROCESSES AND TO PREDICT RESPONSE TO DISEASE THERAPIES ATE516367T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10307114 2003-02-19
DE10348600A DE10348600A1 (en) 2003-02-19 2003-10-20 Use of a gene modification in the human GNAS1 gene to predict disease risks, disease courses and to predict the response to disease therapies
PCT/EP2004/001563 WO2004076690A2 (en) 2003-02-19 2004-02-19 Use of a mutation in the human gnas gene for predicting risks of disease, courses of diseases, and for predicting the response to treatments of disease

Publications (1)

Publication Number Publication Date
ATE516367T1 true ATE516367T1 (en) 2011-07-15

Family

ID=32797558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04712508T ATE516367T1 (en) 2003-02-19 2004-02-19 USE OF A GENETIC MODIFICATION IN THE HUMAN GNAS GENE TO PREDICT RISK OF DISEASE, DISEASE PROCESSES AND TO PREDICT RESPONSE TO DISEASE THERAPIES

Country Status (2)

Country Link
AT (1) ATE516367T1 (en)
DE (1) DE10348600A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015171370A1 (en) 2014-05-05 2015-11-12 Medtronic, Inc. Methods and compositions for scd, crt, crt-d, or sca therapy identification and/or selection

Also Published As

Publication number Publication date
DE10348600A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
SG142154A1 (en) Methods for genomic analysis
EP1948799A4 (en) USE OF BACTERIOCINES TO PROMOTE PLANT GROWTH AND DISEASE RESISTANCE
DE602004020194D1 (en) FUNCTION AND TO OPTIMIZE THE CARDIAL STIMULATION INTERVALS BASED ON LEFT VENTRICULAR WALL MOVEMENT
ATE410126T1 (en) DENTAL NAPDS WITH TAPS AND MEANS TO RELIEF STRESS
DE69938554D1 (en) ELONGASE GENES AND ITS USE
EP1514436A4 (en) TWO-WAVE UPGRADE RATE CONTROL TO ENABLE UPGRADE CLASSIFICATION
DE60134866D1 (en) USE OF IMIDAZOCHINOLINAMINES AS ADJUVANTIES IN DNA VACCINATION
DE602005011915D1 (en) Multiprocessor calculator for distributing tasks based on heat emission and processor temperature
EP2007393A4 (en) THIAZOL AND THIOPHONE ANALOGUE AND THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CARCINOMAS
SG114670A1 (en) New fluorescent genetic fragments and fish
DE602006008827D1 (en) HERBICIDESIS GIVING GENES GRG23 AND GRG51
WO2008014400A3 (en) Crohn disease susceptibility gene
DE60317693D1 (en) METHOD AND USE OF THERMOSTABILES RNA LIGASES
EP1507790A4 (en) FROM HUMAN PROSTATE ISOLATED HUMAN GENES AND GENE EXPRESSION PRODUCTS
ATE465413T1 (en) USE OF ADAM 12 TO DIAGNOSE PREECLAMPSIA
ATE516367T1 (en) USE OF A GENETIC MODIFICATION IN THE HUMAN GNAS GENE TO PREDICT RISK OF DISEASE, DISEASE PROCESSES AND TO PREDICT RESPONSE TO DISEASE THERAPIES
ATE475315T1 (en) AGENTS FOR THE BIOLOGICAL CONTROL OF FUNGAL PLANT DISEASES
DE60322052D1 (en) N-ACYLAMINOACETONITRIL DERIVATIVES AND THEIR USE FOR THE CONTROL OF PARASITES
EP2357229A4 (en) HYDROXYLASE GENE AND USE THEREOF
EP1784209A4 (en) CONTRAZEPTIVA BASED ON SP22 AND SP22 ANTIBODIES
DE502004001713D1 (en) Wax dispersions for use in / as body and hair care products
ATE550943T1 (en) ISOLATED DNA FRAGMENT OF THE HUMAN SPARC PROMOTER AND ITS USE
WO2004076690A3 (en) Use of a mutation in the human gnas gene for predicting risks of disease, courses of diseases, and for predicting the response to treatments of disease
DE60328391D1 (en) USE OF DIGOXIN IMMUN-FAB FOR REGULATING SODIUM / CALIUM ATPASE ACTIVITY IN PATIENTS WITH PRE-CLAMP AND ECLAMPSY
DE502005002035D1 (en) Use of a liquid for the treatment of hard metals